Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the present application.

1. (currently amended) A compound according to formula (I)



(I)

wherein ~~the compound of formula (I) is selected from the group of (i) and (ii) wherein (i) comprises~~

~~X^3 is $(HO)_2PO-Z^1-$;~~

~~one or both of X^1 and X^2 is R^1-Y^1-A- with each being the same or different, or optionally one of X^1 and X^2 is H;~~

~~A is either a direct link, $(CH_2)_k$ with k being an integer from 0 to 30, or O;~~

~~Y^1 is $-(CH_2)_l-$ with l being an integer from 1 to 30, $-O-$, $-S-$, $-\overset{O}{\overset{\|}{C}}-$, or $-NR^2-$;~~

~~Z^1 is $-(CH_2)_m-$ or $-O(CH_2)_m-$ with m being an integer from 1 to 50, $-C(R^2)H-$, $-NH-$, $-O-$, or $-S-$;~~

~~Q^1 and Q^2 are independently H_2, $=NR^4$, $=O$, or a combination of H and $-NR^5R^6$;~~

~~R^1, for each of X^1 and X^2, is independently hydrogen, a straight or branched chain C1 to C30 alkyl, a straight or branched chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring, an arylalkyl including straight or branched chain C1 to C30 alkyl, an aryloxyalkyl including straight or branched chain C1 to C30 alkyl,~~



~~; and~~

~~R^2, R^3, R^4, R^5, R^6, R^7, and R^8 are independently hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acyl including a C1 to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain C1 to C30 alkyl, or an aryloxyalkyl including straight or branched-chain C1 to C30 alkyl;~~

~~wherein (ii) comprises~~

X^1 is $(HO)_2PO—Z^1—$;

~~one or both of~~ X^2 and X^3 ~~is~~ are both $R^1R^2N—$ ~~$R^1—Y^1—A—$~~ with each being the same or different ~~or optionally one of X^2 and X^3 is H~~;

~~A is either a direct link, $(CH_2)_k$ with k being an integer from 0 to 30, or O;~~

~~Y^1 is $(CH_2)_l$ with l being an integer from 1 to 30, O, S,~~

~~  ~~

~~C, or NR^2;~~

Z^1 is ~~$(CH_2)_m$ or~~ $—O(CH_2)_m—$ with m being an integer from 1 to 50, ~~$C(R^3)H$, NH,~~ or ~~O, or S~~;

Q^1 and Q^2 are independently H_2, $=NR^4$, =O, a combination of H and $—NR^5R^6$;

R^1~~, for each of~~ at X^2 ~~or X^3~~; is ~~independently hydrogen,~~ a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, ~~an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring,~~ or an acyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring ~~, an arylalkyl including straight or branched-chain C1 to C30 alkyl, an aryloxyalkyl including straight or branched-chain C1 to C30 alkyl,~~



; and

R^1 at X^3 is hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, or an acyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring; and

R^2, ~~R^3~~, R^4, R^5, and R^6~~, R^7, and R^8~~ are independently hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acyl including a C1 to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain C1 to C30 alkyl, or an aryloxyalkyl including straight or branched-chain C1 to C30 alkyl;

wherein when R^2 at X^2 is H and Q^2 is =O, R^1 is ~~R^1—Y^1—A— with A being a direct link, Y^1 being —NH—, and R^1 being~~ a straight ~~or branched~~ chain ~~alkyl group, the straight or branched chain alkyl group is a~~ C10 ~~C5~~ to ~~C30~~ C18 alkyl group~~; and~~

~~wherein the compound of formula (I) is not lysophosphatidic acid, phosphatidic acid, cyclic phosphatidic acid, alkenyl glycerolphosphate, dioctyl glycerol pyrophosphate, or N palmitoyl-L-serine~~.

2. (canceled)

3. (currently amended) The compound according to claim 1, wherein the compound is from group (ii) and wherein

Q^1 is H_2;

Q^2 is =O;

Z^1 is O; and

R^2 at both X^2 and X^3 is H are ~~R^1—Y^1—A—, with A being a direct link and Y^1 being —NH— for each~~

4. (currently amended) The compound according to claim 3, wherein X^3 is $—NH_2$ and ~~X^2 is —NHR^1 with~~ R^1 at X^2 is ~~being~~ a straight chain C14 to C18 alkyl.

5. (currently amended) The compound according to claim 4, wherein R^1 at X^2 is a C14 alkyl.

6. (currently amended) The compound according to claim 4, wherein R^1 is at X^2 a C18 alkyl.

7. (currently amended) The compound according to claim 3, wherein

~~X^3 is —NHR^1 with~~ R^1 at X^3 is ~~being~~ an acetyl group and

~~X^2 is —NHR^1 with~~ R^1 at X^2 is ~~being~~ a C14 alkyl.

8-11 (canceled)

12. (original) A pharmaceutical composition comprising:

a pharmaceutically-acceptable carrier and

a compound according to claim 1.

13-34 (canceled)